{{Rsnum
|rsid=752822
|Gene=CSNK1A1
|Chromosome=5
|position=149509455
|Orientation=plus
|GMAF=0.2608
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CSNK1A1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 58.4 | 35.4 | 6.2
| HCB | 52.6 | 43.1 | 4.4
| JPT | 33.6 | 46.9 | 19.5
| YRI | 87.8 | 11.6 | 0.7
| ASW | 77.2 | 19.3 | 3.5
| CHB | 52.6 | 43.1 | 4.4
| CHD | 58.7 | 33.0 | 8.3
| GIH | 35.6 | 46.5 | 17.8
| LWK | 58.2 | 37.3 | 4.5
| MEX | 32.8 | 48.3 | 19.0
| MKK | 76.9 | 21.8 | 1.3
| TSI | 49.0 | 47.1 | 3.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs752822
|Name_s=
|Gene_s=CSNK1A1
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.27, combined P value= 1.73E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470203
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs752822
|overall_frequency_n=34
|overall_frequency_d=128
|overall_frequency=0.265625
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=28
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}